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Abstract Rhinitis is a multifactorial disease characterized by
symptoms of sneezing, rhinorrhea, postnasal drip, and nasal
congestion. Non-allergic rhinitis is characterized by rhinitis
symptoms without systemic sensitization of infectious etiolo-
gy. Based on endotypes, we can categorize non-allergic rhini-
tis into an inflammatory endotype with usually eosinophilic
inflammation encompassing at least NARES and LAR and
part of the drug induced rhinitis (e.g., aspirin intolerance)
and a neurogenic endotype encompassing idiopathic rhinitis,
gustatory rhinitis, and rhinitis of the elderly. Patients with
idiopathic rhinitis have a higher baseline TRPV1 expression
in the nasal mucosa than healthy controls. Capsaicin (8-meth-
yl-N-vanillyl-6-nonenamide) is the active component of chili
peppers, plants of the genus Capsicum. Capsaicin is unique
among naturally occurring irritant compounds because the
initial neuronal excitation evoked by it is followed by a
long-lasting refractory period, during which the previously
excited neurons are no longer responsive to a broad range of
stimuli. Patients with idiopathic rhinitis benefit from intranasal
treatment with capsaicin. Expression of TRPV1 is reduced in
patients with idiopathic rhinitis after capsaicin treatment.
Recently, in a Cochrane review, the effectiveness of capsaicin
in the management of idiopathic rhinitis was evaluated and the
authors concluded that given that many other options do not
work well in non-allergic rhinitis, capsaicin is a reasonable
option to try under physician supervision. Capsaicin has not
been shown to be effective in allergic rhinitis nor in other
forms of non-allergic rhinitis like the inflammatory endotypes
or other neurogenic endotypes like rhinitis of the elderly or
smoking induced rhinitis.
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Introduction
Rhinitis is a multifactorial disease characterized symptoms of
sneezing, rhinorrhea, postnasal drip, and nasal congestion.
Rhinitis affects 10–40 % of the population in the industrial-
ized countries, which is responsible for billions of dollars of
healthcare expenditure and impairs the quality of life those
affected [1•]. Rhinitis constitutes a risk factor for asthma and
is associated with chronic conditions such as rhinosinusitis
[2••]. Classification of rhinitis entities on the basis of pheno-
types has facilitated their characterization and has helped prac-
ticing clinicians to efficiently approach rhinitis patients [2••].
Allergic rhinitis (AR) is defined as a symptomatic disorder of
the nose induced by an IgE-mediated inflammation after aller-
gen exposure of the membranes lining the nose. Non-allergic
rhinitis (NAR) is characterized by rhinitis symptoms without
systemic sentization of infectious etiology. A number of dif-
ferent phenotypes exists of which the most important are idi-
opathic rhinitis and irritative-induced rhinitis, like smokers
rhinitis, drug-induced rhinitis, gustatory rhinitis, non-allergic
rhinitis with eosinophilia syndrome (NARES), atrophic rhini-
tis, rhinitis of the elderly, and hormonally induced rhinitis [2••,
3]. Some of these phenotypes, like rhinitis of the elderly, have
very clear characteristics: watery rhinorrhea without other sig-
nificant rhinitis symptoms, but other forms are not so easy to
discriminate and sometimes also overlap. In between NAR
and AR is another disease called local allergic rhinitis (LAR)
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that is characterized by local IgE without systemic sensitiza-
tion but with allergen-induced symptoms. Although there are
some data pointing to about half of the rhinitis patients having
NAR, the prevalence of the various phenotypes of NAR is
largely unknown. To make things more complicated, patients
may have a phenotype called mixed rhinitis with components
of NAR and AR, e.g., a patient with seasonal allergic symp-
toms based on AR but perennial non-allergic symptoms.
Finally, the so-called hyperreactivity is an increased sensitiv-
ity of the nasal mucosa to various non-specific stimuli. Both
allergic rhinitis (AR) and non-allergic rhinitis (NAR) patients
can elicit nasal hyperreactivity symptoms, and no quantitative
or qualitative differences in nasal hyperreactivity can be found
between AR and NAR patients [4•]. Moreover, it is not pos-
sible to differentiate NAR subpopulations based on physical
or chemical stimuli [4•].
When we try to define NAR based on endotypes, we might
say that at least there is an inflammatory endotype with usu-
ally eosinophilic inflammation encompassing at least NARES
and LAR and part of the drug induced rhinitis (e.g., aspirin
intolerance) [5, 6••]. Another clear endotype is the neurogenic
endotype encompassing idiopathic rhinitis, gustatory rhinitis,
and rhinitis of the elderly and other phenotypes with a strong
neurological component [6••].
Diagnosing NAR
NAR is clinically usually diagnosed based on a thorough his-
tory and a SPT to rule out AR.
In epidemiological research, it is possible to rule out AR
with the proper questions in a fairly accurate way [7]. In clin-
ical research, NAR is diagnosed by a positive reaction to CDA
[8, 9]. Histamine, methacholine, and capsaicin have been
shown not to be able to discriminate NAR patients from
healthy controls [3]. A PNIF meter can be provided to take
home in case patients complain of hyperreactivity attacks with
nasal obstruction [10, 11]. Many patients with NAR have
uncontrolled disease [12].
Pathophysiology of Neurogenic Rhinitis Endotype
The neural regulation of the upper airways is complex and
consists of a number of interacting nervous systems.
Sensory, parasympathetic, and sympathetic nerves regulate
epithelial, vascular, and glandular processes in the nasal
mucosa.
Sensory nerves originating form ethmoidal and
nasopalatine branches of the trigeminal nerve transmit afferent
sensory input from the nasal epithelium, blood vessels, and
secretory glands. These nerve endings extend close to the
nasal epithelial surface and between tight junctions of epithe-
lial cells. These nerve fibers respond to environmental irritants
such as cigarette smoke, pain, and variations in temperature
and osmolarity and thus play an important role in NAR.
Activation of nasal afferent nerves by aspecific factors results
in defensive efferent responses, such as sneezing, and glandu-
lar and/or vascular activation, leading to rhinorrhea and nasal
congestion. Both transient receptor potential ankyrin 1
(TRPA1) and vanilloid 1 (TRPV1) receptors are abundantly
expressed in these C-fiber sensory nerves and can be activated
by a number of endogenous inflammatory mediators [6••,
13•]. C fibers are often defined as falling within two broad
categories, peptidergic and non-peptidergic. The peptidergic
C fibers can also locally release neuropeptides (antidromic
pathway) such as substance P or calcitonin gene related-
peptide (CGRP) after stimulation of the TRP receptors. This
neuropeptides release gives rise to vasodilation, extravasation
and hypersecretion resulting in symptoms of rhinitis. Patients
with idiopathic rhinitis compared to healthy controls have
been shown to overexpress TRPV1 in the nasal mucosa, and
they have increased SP levels in nasal secretions [14••].
Apart from the potential dysregulation in the sensory
nerves, an imbalance of the efferent nasal reflex arc of the
autonomic nerve supply to the nasal plays a role in some
forms of NAR. Equal contributions from both components
maintain a balance between the vasoconstriction and vasodi-
lation of nasal vasculature and stimulation of serous glands.
An imbalance of these components leads to glandular hyper-
secretion and plays an important role, e.g., in rhinitis of the
elderly. The anticholinergic agent ipratropium bromide is a
highly effective treatment for hypersecretion in idiopathic rhi-
nitis [15, 16] but does not have any influence on other symp-
toms like nasal blockage or sneezing [17, 18].
Capsaicin
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is the active
component of chili peppers, plants of the genus Capsicum.
Along with other related compounds, it belongs to a group of
chemicals identified as capsaicinoids. Capsaicin produces a
burning sensation when a tissue comes into contact with it.
This occurs via binding to transient receptor potential vanilloid
1 (TRPV1) receptor, an ion channel-type receptor, which can
be stimulated by heat and physical abrasion. Capsaicin is
unique among naturally occurring irritant compounds because
the initial neuronal excitation evoked by it is followed by a
long-lasting refractory period, during which the previously ex-
cited neurons are no longer responsive to a broad range of
stimuli. This process known as defunctionalization has been
exploited for therapeutic use of capsaicin in various painful
conditions [19]. A beneficial role of capsaicin has been report-
ed in obesity, cardiovascular and gastrointestinal conditions,
various cancers, neurogenic bladder, and dermatologic condi-
tions [19]. Recent studies focusing on tumor immunity, allergy,
and inflammation have noted the immunotherapeutic effects of
capsaicin [20–23]. In a large prospective study of over 0.5
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million adults from ten geographically diverse areas across
China, the habitual consumption of spicy food was found to
be inversely related with total and specific mortality [24].
When sprayed in the nose, capsaicin induces burning,
rhinorrhea, nasal blockage, and lacrimation. TRPV1 activa-
tion leads to a cationic influx in the nerve terminals, resulting
in neuronal excitation, an increase in intracellular Ca2+ con-
centration, and antidromic release of neuropeptides, which
potentially triggers a local inflammatory response. The thera-
peutic effect of intranasal capsaicin application is thought to
be induced by the abovementioned defunctionalization and/or
degeneration of nerve terminals by the massive Ca2+ influx.
For unclear reasons, most patients with IR only experience the
recurrence of nasal symptoms after several months and sub-
sequently seek the reapplication of capsaicin. In a study com-
paring patients with idiopathic rhinitis and controls, van
Gerven et al. reported that patients with IR had higher baseline
transient receptor potential cation channel subfamily V, recep-
tor 1 (TRPV1) expression in the nasal mucosa, and higher
concentrations of substance P (SP) in nasal secretions than
healthy controls. Expression of TRPV1, transient receptor po-
tential cation channel subfamily M, receptor 8 (TRPM8), and
protein gene product 9.5 (PGP 9.5) was reduced in patients
with IR after capsaicin treatment. Capsaicin did not alter the
mast cell marker c-KITor nasal epithelial morphology nor did
it induce apoptosis or necrosis in cultured human nasal epi-
thelial cells and mast cells [14••]. Azelastine has also been
found to be clinically effective in the treatment of NAR, but
its mechanism(s) of action is still poorly elucidated. Using
in vitro cell line mice neuronal cells as surrogates for submu-
cosal sensory neurons, and human nasal epithelial cells
(hNEC), Singh et al. showed that azelastine, similar to capsa-
icin, exhibits direct activity on TRPV1 ion channels that may
represent a novel mechanistic pathway explaining its clinical
efficacy in NAR [25•]. Also, a recent study has determined the
inhibition of TRPV1 but not TRPA1 channels by tiotropium
and ipratropium [26•]. These studies suggest that symptoms
mediated by neuronal TRPV1 are inhibited by tiotropium via
mechanisms distinct from its anticholinergic action [6••, 26•].
Capsaicin in AR
One small trial did not find evidence that intranasal capsaicin
had a therapeutic effect in allergic rhinitis [27•]. A small phar-
macological effect on clinical histamine dose response was
found. After treatment, leukotriene levels in nasal lavage did
not increase in the capsaicin group [27•]. Also, a TRPV1
blocker had no effect on total symptom score, PNIF and
ECP levels in allergen-challenged patients with seasonal aller-
gic rhinitis. The individual symptoms, nasal itch or sneezes,
were also not affected [28]. These findings may indicate that
TRPV1 is not a key mediator of the symptoms in allergic
rhinitis. However, additional studies, using drug formulations
with a prolonged duration of action, should be conducted be-
fore TRPV1 is ruled out as a drug target in allergic rhinitis
[28].
Capsaicin in NAR
Patients with idiopathic rhinitis benefit from intranasal treat-
ment with capsaicin (i.e., the main pungent agent in hot chili
peppers). In 1997, Blom et al. published the first placebo-
controlled trial showing therapeutic efficacy [29, 30].
Recently, in a Cochrane review, the effectiveness of capsa-
icin in the management of idiopathic rhinitis was evaluated
[31••]. Overall, the quality of the evidence was judged to be of
low tomoderate quality. The authors concluded that given that
many other options do not work well in non-allergic rhinitis,
capsaicin is a reasonable option to try under physician
supervision.
Four studies (five publications) involving 302 adult pa-
tients with moderate-severe idiopathic rhinitis were analyzed.
Two studies compared capsaicin to placebo [29, 30, 32]; one
study compared two treatment regimens of capsaicin: five
treatments in 1 day versus five treatments given every 2 to
3 days during 2 weeks [33]. The study by Ciabatti, in addition
to comparing capsaicin with placebo, also compared three
different doses of capsaicin to each other [32]. Finally,
Havas et al. compared capsaicin with budesonide [34].
The studies in the Cochrane review had follow-up periods
ranging from 4 to 38 weeks [31••]. Of the two studies that
compared capsaicin with placebo, one study reported that cap-
saicin resulted in an improvement of overall nasal symptoms
(a primary outcome) measured on a visual analogue scale
(VAS) of 0 to 10 [29, 30]. There was a mean difference
(MD) of −3.34 (95 % confidence interval (CI) −5.24 to
−1.44), MD −3.73 (95 % CI −5.45 to −2.01) and MD −3.52
(95 % CI −5.55 to −1.48) at 2, 12, and 36 weeks posttreat-
ment, respectively. The other study reported that, compared to
placebo, capsaicin (at 4 μg/puff) was more likely to produce
overall symptom resolution (reduction in nasal blockage,
sneezing/itching/coughing, and nasal secretion measured with
a daily record chart) at 4 weeks posttreatment (a primary out-
come) [32]. The risk ratio (RR) was 3.17 (95 % CI 1.38 to
7.29). In the study that compared capsaicin to budesonide, it
was shown that patients treated with capsaicin had a better
overall symptom score compared to those treated with
budesonide (MD 2.50, 95 % CI 1.06 to 3.94, VAS of 0 to
10) [34]. The last study compared two different regimens of
capsaicin administration: five treatments in 1 day versus five
treatments given every 2 to 3 days during 2 weeks [33]. Using
daily record charts, the study showed comparable results
whether treatment was given as five treatments every other
2–3 days or five times in 1 day with hours between the
applications.
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One study measured the levels of leukotrienes C4/D4/E4,
prostaglandin D2, and tryptase in the nasal lavage and the
expression of CD1, CD3, CD25, CD68, IgE, MBP (i.e.,
BMK13 antibody), chymase, tryptase, synaptophysin, and
neurofilament and found no statistically significant differ-
ences between the groups [29, 30]. Capsaicin treatment has
been shown to be safe: blood pressure, heart rate, olfactory
function, and mucosal sensibility are not affected by the treat-
ment [33]. The treatment effect lasts at least 1 year and can
easily be repeated [3].
In the Cochrane review, one randomized, placebo-con-
trolled, double-blind, parallel study of 21 days total duration
(7 days pre-treatment and 14 days during treatment), which
compared Sinus Buster (a homeopathic preparation of
Capsicum annuum and Eucalyptol) with placebo (filtered wa-
ter) was excluded because the dosage of Capsaicin was un-
clear [31••, 35]. The participants were patients with non-
allergic rhinitis and mixed rhinitis. Results of this study
showed improvement in total nasal symptom score, nasal
pain, headache, and sinus pressure compared with placebo
with a self-reported quick onset of action (less than a minute)
[35].
Conclusions
To our knowledge, there are no studies available to evaluate
the effect of capsaicin in other forms of NAR. In the experi-
ence of the author of this paper, capsaicin is not effective in
rhinitis of the elderly or in NAR caused by smoking.
For now, capsaicin nasal spray, with adequate concentra-
tion, is not produced commercially and thus needs some at-
tention to be produced by the (hospital) pharmacist. The now
available commercial products have unknown concentrations
of capsaicin but may be also effective [35]. New drugs
targeting TRPV1 are developed [36] and may offer the poten-
tial to control medical conditions characterized by sensory
neuronal hyper-responsiveness, including the nasal hyper-
reactivity that underlies NAR [37].
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